Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
Titel:
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
Auteur:
Keating, Claire Yonker, Lael M Vermeulen, François Prais, Dario Linnemann, Rachel W Trimble, Aaron Kotsimbos, Tom Mermis, Joel Braun, Andrew T O'Carroll, Mark Sutharsan, Sivagurunathan Ramsey, Bonnie Mall, Marcus A Taylor-Cousar, Jennifer L McKone, Edward F Tullis, Elizabeth Floreth, Tim Michelson, Peter Sosnay, Patrick R Nair, Nitin Zahigian, Rachel Martin, Hannah Ahluwalia, Neil Lam, Anna Horsley, Alexander
Verschenen in:
Lancet respiratory medicine
Paginering:
Jaargang 13 () nr. 3 pagina's 256-271
Jaar:
2025
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license